Details for Patent: 8,592,397
✉ Email this page to a colleague
Which drugs does patent 8,592,397 protect, and when does it expire?
Patent 8,592,397 protects ATRIPLA, COMPLERA, STRIBILD, and TRUVADA, and is included in four NDAs.
This patent has sixty-two patent family members in twenty-nine countries.
Summary for Patent: 8,592,397
| Title: | Compositions and methods for combination antiviral therapy |
| Abstract: | The present invention relates to therapeutic combinations of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread.RTM.) and (2R, 5S, cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimi- din-2-one(emtricitabine, Emtriva.TM., (-)-cis FTC) and their physiologically functional derivatives. The combinations may be useful in the treatment of HIV infections, including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors. The present invention is also concerned with pharmaceutical compositions and formulations of said combinations of tenofovir disoproxil fumarate and emtricitabine, and their physiologically functional derivatives, as well as therapeutic methods of use of those compositions and formulations. |
| Inventor(s): | Dahl; Terrence C. (Sunnyvale, CA), Menning; Mark M. (San Francisco, CA), Oliyai; Reza (San Carlos, CA) |
| Assignee: | Gilead Sciences, Inc. (Foster City, CA) |
| Application Number: | 12/195,161 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,592,397 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; Dosage form; Use; |
Drugs Protected by US Patent 8,592,397
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences | ATRIPLA | efavirenz; emtricitabine; tenofovir disoproxil fumarate | TABLET;ORAL | 021937-001 | Jul 12, 2006 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER | ⤷ Sign Up | |||
| Gilead Sciences | ATRIPLA | efavirenz; emtricitabine; tenofovir disoproxil fumarate | TABLET;ORAL | 021937-001 | Jul 12, 2006 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | TREATMENT OF HIV-1 INFECTION IN ADULTS | ⤷ Sign Up | |||
| Gilead Sciences Inc | COMPLERA | emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate | TABLET;ORAL | 202123-001 | Aug 10, 2011 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | TREATMENT OF HIV INFECTION | ⤷ Sign Up | |||
| Gilead Sciences Inc | STRIBILD | cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate | TABLET;ORAL | 203100-001 | Aug 27, 2012 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | TREATMENT OF HIV INFECTION | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,592,397
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| African Regional IP Organization (ARIPO) | 2089 | ⤷ Sign Up | |||
| Argentina | 040805 | ⤷ Sign Up | |||
| Argentina | 043332 | ⤷ Sign Up | |||
| Argentina | 101679 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
